Old drug new use - Amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity

Clinical Cancer Research

Volumn 20, Issue 13, 2014, Pages 3521-3530

  Kong, Ren ^a   Liu, Timothy ^a   Zhu, Xiaoping ^a   Ahmad, Syed ^c   Williams, Alfred L ^c   Phan, Alexandria T ^b   Zhao, Hong ^a   Scott, John E ^c   Yeh, Li An ^c   Wong, Stephen T C ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYAMOXAPINE; 8 HYDROXYAMOXAPINE; AMOXAPINE; BETA GLUCURONIDASE; DRUG METABOLITE; IRINOTECAN; LOXAPINE; UNCLASSIFIED DRUG; 7-HYDROXYAMOXAPINE; 8-HYDROXYAMOXAPINE; ANTINEOPLASTIC AGENT; BETA-GLUCURONIDASE INHIBITOR; CAMPTOTHECIN; GLYCOPROTEIN; PROTECTIVE AGENT; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; CONFORMATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; MOLECULAR DOCKING; MORTALITY; NEOPLASMS; PATHOLOGY; TOXICITY; TUMOR CELL LINE;

AMOXAPINE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; GLYCOPROTEINS; MICE; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; NEOPLASMS; PROTECTIVE AGENTS; PROTEIN BINDING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903837906     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0395     Document Type: Article

References (44)

1. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6: 789-802.
2. Tam VC, Rask S, Koru-Sengul T, Dhesy-Thind S. Generalizability of toxicity data from oncology clinical trials to clinical practice: toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer. Curr Oncol 2009;16: 13-20.
3. Abigerges D, Armand J-P, Chabot GG, Costa LD, Fadel E, Cote C, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994;86: 446-9.
4. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, Nagai E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 1994;17: 662-4.
5. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51: 4187-91.
6. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998;101: 847-54.
7. Chen S, Yueh MF, Bigo C, Barbier O, Wang K, Karin M, et al. Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11). Proc Natl Acad Sci U S A 2013.
8. Kaneda N, Yokokura T. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 1990;50: 1721-5.
9. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, et al. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996;56: 3752-7.
10. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, et al. Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 1998;42: 280-6.
11. Sparreboom A, de Jonge MJ, de Bruijn P, Brouwer E, Nooter K, Loos WJ, et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 1998;4: 2747-54.
12. Hu ZP, Yang XX, Chan SY, Xu AL, Duan W, Zhu YZ, et al. St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis. Toxicol Appl Pharmacol 2006;216: 225-37.
13. Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010;330: 831-5.
14. Roberts AB, Wallace BD, Venkatesh MK, Mani S, Redinbo MR. Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol Pharmacol 2013;84: 208-17.
15. Ahmad S, Hughes MA, Lane KT, Redinbo MR, Yeh LA, Scott JE. A high throughput assay for discovery of bacterial β-glucuronidase inhibitors. Curr Chem Genomics 2011;5: 13-20.
16. Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature 2007;448: 645-6.
17. Ahmad S, Hughes MA, Yeh L-A, Scott JE. Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors. J Biomol Screen 2012;17: 957-65.
18. Calvo B, Garcia MJ, Pedraz JL, Marino EL, Dominguez-Gil A. Pharmacokinetics of amoxapine and its active metabolites. Int J Clin Pharmacol Ther Toxicol 1985;23: 180-5.
19. Schrodinger 2011. New York, NY: Schrodinger, LLC; 2011.
20. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, et al. Gaussian 09, Revision A.1. Wallingford, CT: Gaussian, Inc.; 2009.
21. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 2006;65: 712-25.
22. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem 2004;25: 1157-74.
23. Case DA, TAD, Cheatham TE III, Simmerling CL, Wang J, Duke RE, et al. AMBER 11. San Francisco, CA: University of California; 2010.
24. Ryckaert J, Ciccotti G, Berendsen H. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 1977;23: 327-41.
25. Darden T, York D, Pedersen L. Particle mesh Ewald: an N [center-dot] log(N) method for Ewald sums in large systems. J Chem Phys 1993;98: 10089-92.
26. Izaguirre J, Catarello D, Wozniak J, Skeel R. Langevin stabilization of molecular dynamics. J Chem Phys 2001;114: 2090-8.
27. Hou T, Wang J, Li Y, Wang W. Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model 2011;51: 69-82.
28. Yang T, Wu JC, Yan C, Wang Y, Luo R, Gonzales MB, et al. Virtual screening using molecular simulations. Proteins: Struct. Funct Bioinformatics 2011;79: 1940-51.
29. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 2000;33: 889-97.
30. Zhao J, Huang L, Belmar N, Buelow R, Fong T. Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res 2004;10: 2851-9.
31. Brandi G, Dabard J, Raibaud P, Di Battista M, Bridonneau C, Pisi AM, et al. Intestinal microflora and digestive toxicity of irinotecan in mice. Clin Cancer Res 2006;12: 1299-307.
32. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22: 659-61.
33. de Jong FA, Kehrer DFS, Mathijssen RHJ, Creemers G-J, de Bruijn P, van Schaik RHN, et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist 2006;11: 944-54.
34. Cummings JH, Macfarlane GT. Role of intestinal bacteria in nutrient metabolism. JPEN J Parenter Enteral Nutr 1997;21: 357-65.
35. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;361: 512-9.
36. Takeda Y, Kobayashi K, Akiyama Y, Soma T, Handa S, Kudoh S, et al. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 2001;92: 269-75.
37. Palmeira A, Rodrigues F, Sousa E, Pinto M, Vasconcelos MH, Fernandes MX. New uses for old drugs: pharmacophore-based screening for the discovery of P-glycoprotein inhibitors. Chem Biol Drug Des 2011;78: 57-72.
38. Jansen WJ, Hulscher TM, van Ark-Otte J, Giaccone G, Pinedo HM, Boven E. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. Br J Cancer 1998;77: 359-65.
39. Ban TA, Wilson WH, McEvoy JP. Amoxapine: a review of literature. Int Pharmacopsychiatry 1980;15: 166-70.
40. Cooper TB, Kelly RG. GLC analysis of loxapine, amoxapine, and their metabolites in serum and urine. J Pharm Sci 1979;68: 216-9.
41. Takeuchi H, Yokota S, Shimada S, Ohtani Y, Miura S, Kubo H. Pharmacokinetics of amoxapine and its active metabolites in healthy subjects. Curr Ther Res Clin Exp 1993;53: 427-34.
42. Khanna R, Morton CL, Danks MK, Potter PM. Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res 2000;60: 4725-8.
43. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000;60: 1189-92.
44. Wadkins RM, Hyatt JL, Yoon KJ, Morton CL, Lee RE, Damodaran K, et al. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol Pharmacol 2004;65: 1336-43.